Poor health literacy increases risk of medication side-effects

The risk of serious side-effects associated with a common blood-thinning medication are related to elderly patients misunderstanding medical instructions, according to new research.

A team of researchers at Monash University studied the effects of warfarin, a drug that has been used clinically for over 50 years for the prevention of in the elderly, but also puts its patients at an increased risk of bleeding.

The NHMRC-funded research, led by PhD scholar Basia Diug, found that such as poor , and impaired cognition were just as likely to cause an increased risk of bleeding as other factors, such as a patient’s age.

“Warfarin is an effective drug for treatment and prophylaxis of thromboembolic disorders, but despite routine monitoring, patients taking warfarin are at risk of haemorrhage,” Ms. Diug said.

“Most conditions requiring warfarin manifest in older patients, the fastest growing group in our community, and require long-term care.

“Despite the known risks, warfarin usage in Australia has been steadily increasing at a rate of nine per cent annually and it remains one of the leading causes of harmful medication errors and medication-related adverse events.”

The study recommended that doctors consider the social circumstances of patients when prescribing , as the presence of multiple psychosocial deficits increased the risk of bleeding.

Ms. Diug’s research was supervised by Professor John McNeil, Department of Epidemiology and Preventive Medicine, and conducted over two stages, involving over 500 patients recruited through Melbourne Pathology. The results were published in the international journal Stroke and the Medical Journal of Australia.

The project was a collaboration between the Monash Faculty of Medicine, Nursing and Health Sciences, Faculty of Pharmacy and Pharmaceutical Sciences and experts from The Alfred hospital and Melbourne Pathology.

Director of Pharmacy at Alfred Health and Professor of Clinical Pharmacy at the Monash University Centre for Medicine Use and Safety (CMUS), Professor Michael Dooley, collaborated with Ms Diug on the project.

“This work demonstrates the collaboration between clinicians and researchers across faculty lines that are a key component of the strength of having conjoint positions between the acute health care sector and academia,” Professor Dooley said.

add to favorites email to friend print save as pdf

Related Stories

Blood-Thinning Drug Linked to Increased Bleeding in Brain

Sep 29, 2008

(PhysOrg.com) -- Patients who take the commonly used blood-thinning drug warfarin face larger amounts of bleeding in the brain and increased risk of mortality if they suffer a hemorrhagic stroke, new research from the University ...

New blood-thinning drug safer than rat poison

Sep 29, 2009

In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments